The American Diabetes Association (ADA)“Standards of Care in Diabetes” includes the
ADA's current clinical practice recommendations and is intended to provide the components …

The past 50 years have seen a growing ageing population with an increasing prevalence of
type 2 diabetes mellitus (T2DM); now, nearly half of all individuals with diabetes mellitus are …

The American Diabetes Association (ADA)“Standards of Medical Care in Diabetes” includes
the ADA's current clinical practice recommendations and is intended to provide the …

Dipeptidyl peptidase 4 inhibitors (DPP4i) have been available for treating type 2 diabetes
mellitus since 2006. Although they are a diverse group, DPP4i are all small, orally available …

Cardiovascular disease (CVD) is a major challenge in the management of type 2 diabetes
mellitus. Glucose-lowering agents that reduce the risk of major cardiovascular events would …

Abstract Dipeptidyl peptidase 4 (DPP4) inhibitors (DPP4is) are oral anti-diabetic drugs
(OADs) for the treatment of type 2 diabetes mellitus (T2DM) through inhibiting the …

People with type 2 diabetes form a heterogeneous group. Consequently, treatment
regimens and therapeutic targets should be individualized. The treatment of type 2 diabetes …

OBJECTIVE Data regarding the effects of sodium–glucose cotransporter 2 inhibitors in the
elderly (age≥ 65 years) and very elderly (age≥ 75 years) are limited. RESEARCH DESIGN …

Treatment of older adults with type 2 diabetes (T2D) is complex because they represent a
heterogeneous group with a broad range of comorbidities, functional abilities …

ABSTRACT Introduction: Dipeptidyl peptidase-4 inhibitors (DPP-4is) are generally
considered as glucose-lowering agents with a safe profile in type 2 diabetes. Areas covered …